1. Home
  2. SPHL vs GRI Comparison

SPHL vs GRI Comparison

Compare SPHL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPHL
  • GRI
  • Stock Information
  • Founded
  • SPHL 2002
  • GRI 2018
  • Country
  • SPHL Singapore
  • GRI United States
  • Employees
  • SPHL N/A
  • GRI N/A
  • Industry
  • SPHL Homebuilding
  • GRI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SPHL Consumer Discretionary
  • GRI Health Care
  • Exchange
  • SPHL Nasdaq
  • GRI Nasdaq
  • Market Cap
  • SPHL 4.9M
  • GRI 4.9M
  • IPO Year
  • SPHL 2024
  • GRI N/A
  • Fundamental
  • Price
  • SPHL $0.65
  • GRI $1.94
  • Analyst Decision
  • SPHL
  • GRI Strong Buy
  • Analyst Count
  • SPHL 0
  • GRI 2
  • Target Price
  • SPHL N/A
  • GRI $22.50
  • AVG Volume (30 Days)
  • SPHL 2.3M
  • GRI 203.7K
  • Earning Date
  • SPHL 12-29-2025
  • GRI 11-13-2025
  • Dividend Yield
  • SPHL N/A
  • GRI N/A
  • EPS Growth
  • SPHL N/A
  • GRI N/A
  • EPS
  • SPHL N/A
  • GRI N/A
  • Revenue
  • SPHL $5,956,226.00
  • GRI N/A
  • Revenue This Year
  • SPHL N/A
  • GRI N/A
  • Revenue Next Year
  • SPHL N/A
  • GRI N/A
  • P/E Ratio
  • SPHL N/A
  • GRI N/A
  • Revenue Growth
  • SPHL N/A
  • GRI N/A
  • 52 Week Low
  • SPHL $0.35
  • GRI $1.10
  • 52 Week High
  • SPHL $7.80
  • GRI $22.95
  • Technical
  • Relative Strength Index (RSI)
  • SPHL 55.63
  • GRI 49.33
  • Support Level
  • SPHL $0.49
  • GRI $1.89
  • Resistance Level
  • SPHL $0.70
  • GRI $2.27
  • Average True Range (ATR)
  • SPHL 0.09
  • GRI 0.16
  • MACD
  • SPHL 0.00
  • GRI -0.01
  • Stochastic Oscillator
  • SPHL 44.44
  • GRI 32.65

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: